share_log

6-K: AstraZeneca Invests $3.5 Billion in US

6-K: AstraZeneca Invests $3.5 Billion in US

6-K:阿斯利康在美國投資35億美元
美股SEC公告 ·  2024/11/12 22:28

Moomoo AI 已提取核心訊息

AstraZeneca has announced a $3.5 billion capital investment in the United States to expand its research and manufacturing capabilities by the end of 2026. The investment includes $2 billion in new funding that will create over 1,000 high-skilled jobs, focusing on establishing a state-of-the-art R&D center in Cambridge, Massachusetts, next-generation biologics facility in Maryland, cell therapy manufacturing on both coasts, and specialty manufacturing in Texas.The investment aligns with AstraZeneca's Ambition 2030 strategy to achieve $80 billion in Total Revenue by 2030, with particular emphasis on accelerating development in the United States, which currently generates 44% of the company's total revenue. The company maintains a significant US presence with approximately 17,800 employees across 17 R&D, manufacturing, and commercial sites in 12 states.
AstraZeneca has announced a $3.5 billion capital investment in the United States to expand its research and manufacturing capabilities by the end of 2026. The investment includes $2 billion in new funding that will create over 1,000 high-skilled jobs, focusing on establishing a state-of-the-art R&D center in Cambridge, Massachusetts, next-generation biologics facility in Maryland, cell therapy manufacturing on both coasts, and specialty manufacturing in Texas.The investment aligns with AstraZeneca's Ambition 2030 strategy to achieve $80 billion in Total Revenue by 2030, with particular emphasis on accelerating development in the United States, which currently generates 44% of the company's total revenue. The company maintains a significant US presence with approximately 17,800 employees across 17 R&D, manufacturing, and commercial sites in 12 states.
阿斯利康宣佈在美國投資35億美金,以在2026年底之前擴大其研發和製造能力。這項投資包括20億美金的新資金,將創造超過1000個高技能職位,重點建設位於馬薩諸塞州劍橋的先進研發中心、位於馬里蘭州的下一代生物製品設施、兩岸的電芯治療製造,以及位於德克薩斯州的專業製造。這項投資與阿斯利康的2030年雄心策略相一致,目標是在2030年實現800億美金的營業收入,特別強調加速在美國的發展,目前美國佔公司總營業收入的44%。公司在美國擁有約17800名員工,在12個州的17個研發、製造和商業基地中運營。
阿斯利康宣佈在美國投資35億美金,以在2026年底之前擴大其研發和製造能力。這項投資包括20億美金的新資金,將創造超過1000個高技能職位,重點建設位於馬薩諸塞州劍橋的先進研發中心、位於馬里蘭州的下一代生物製品設施、兩岸的電芯治療製造,以及位於德克薩斯州的專業製造。這項投資與阿斯利康的2030年雄心策略相一致,目標是在2030年實現800億美金的營業收入,特別強調加速在美國的發展,目前美國佔公司總營業收入的44%。公司在美國擁有約17800名員工,在12個州的17個研發、製造和商業基地中運營。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息